Is 000915 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6
Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 000915 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 000915 (CN¥26.53) is trading below our estimate of fair value (CN¥52.56)
Significantly Below Fair Value: 000915 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 000915?
Key metric: As 000915 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
The above table shows the Price to Earnings ratio for 000915. This is calculated by dividing 000915's market cap by their current
earnings.
What is 000915's PE Ratio?
PE Ratio
12.7x
Earnings
CN¥489.89m
Market Cap
CN¥6.08b
000915 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Price-To-Earnings vs Industry: 000915 is good value based on its Price-To-Earnings Ratio (12.7x) compared to the CN Pharmaceuticals industry average (32.3x).
Price to Earnings Ratio vs Fair Ratio
What is 000915's PE Ratio
compared to its
Fair PE Ratio?
This is the expected PE Ratio taking into
account the company's forecast earnings growth, profit margins
and other risk factors.
000915 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio
12.7x
Fair PE Ratio
21.5x
Price-To-Earnings vs Fair Ratio: 000915 is good value based on its Price-To-Earnings Ratio (12.7x) compared to the estimated Fair Price-To-Earnings Ratio (21.5x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.